ASH 2021 | Predicting the outcomes of patients with AML treated with CPX-351 based on ELN risk stratification

CPX-351 is approved for the treatment of patients with newly diagnosed treatment-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, outlines the findings from a study comparing the outcomes of patients with AML treated with first-line CPX-351 based on their 2017 European Leukemia Net (ELN) risk classification. In this study of 118 patients, the complete remission (CR)/ complete remission with incomplete hematologic recovery (CRi) rate for the favorable- and intermediate-risk groups were significantly higher than the adverse risk group. Overall survival (OS) and the rate of relapse was not significantly different between the three risk groups. OS was significantly longer in intermediate-risk patients who underwent allogeneic stem cell transplant (alloSCT) in comparison to patients who were not transplanted, suggesting alloSCT should be considered in intermediate-risk patients after treatment with CPX-351. In the adverse risk patients, there was no significant difference in OS between the transplanted patients and the non-transplanted patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.